Trial Profile
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- 27 Nov 2023 Planned End Date changed from 31 Jan 2024 to 31 Jan 2025.
- 27 Nov 2023 Planned primary completion date changed from 31 Jan 2024 to 31 Jan 2025.
- 01 Jun 2023 Planned End Date changed from 1 Jan 2023 to 31 Jan 2024.